Ashland, Inc. Q2 FY2025 earnings call

Management Statement and Operational Highlights

• Portfolio Optimization: Completion of Avoca divestiture completed strategic portfolio realignment, focusing on profitable growth.
• Cost Savings: On track to achieve $90 million cost savings target, with $30 million restructuring complete and $60 million manufacturing optimization underway.
• Strategic Priorities: Focus on enhancing financial performance through controllable factors, including globalization and innovation initiatives. Innovation Day upcoming to showcase technology platforms.
• Tariff Management: Proactively navigating tariff landscape, with strategies to optimize supply chain and pricing to minimize impact.

Segment Performance

• Life Science: Sales declined 23% year-over-year to $172 million. Adjusted EBITDA decreased by 15% to $56 million, with a margin of 32.6%. Volume momentum and demand recovery in Pharma were noted, though Nutrition faced some challenges.
• Intermediates: Sales were $37 million, down from $40 million in the prior year. Adjusted EBITDA was $2 million, with a margin of 5.4%. Margin was below expectation due to pricing pressures and reduced production.
• Personal Care: Sales decreased 14% year-over-year to $146 million. Adjusted EBITDA declined 2% to $44 million, with a margin of 30.1%. Resilience in core additives was seen, but biofunctional actives and oral care faced challenges.
• Specialty Additives: Sales fell 15% to $134 million. Adjusted EBITDA declined 4% to $26 million, with a margin of 19.4%. Volume declines in China and competitive intensity in export markets were offset by strong execution in other areas.

Guidance

• Adjusted fiscal 2025 sales to be in the range of $1.825 billion to $1.9 billion.
• Adjusted EBITDA expected to be between $400 million and $420 million.
• Outlook adjusted due to increasing macroeconomic uncertainty, softening consumer demand, and subdued European market recovery.

Risks

• Macroeconomic Uncertainty: Growing global macroeconomic and geopolitical uncertainties impacting consumer confidence and demand.
• Tariff Impacts: Ongoing uncertainty in global trade policy and potential tariff impacts on supply chain and pricing.
• Competitive Intensity: High competitive pressure in certain regions like China, Middle East, Africa, and India affecting volumes and pricing.

Question and Answer

• Q: About order volatility and $70 million of U.S.-produced China sales: A: Volatility reduced, with volumes picking up. Mitigation of risk in U.S.-produced China sales is in progress with customer partnerships.
• Q: Specialty Additives and China competitive pressure: A: China has stable volumes at the bottom, with competitive intensity ongoing but manageable through volume-price balancing.
• Q: Cash flow expectations: A: Free cash flow expectations depend on EBITDA, working capital, FX, and restructuring, with uncertainty around tariff impacts.
• Q: Personal Care margins and EBITDA guidance: A: Personal Care margins expanded to 30%, with Q4 expected to be stronger than Q3 due to restructuring and optimization.
• Q: Coatings additives share loss and customer-specific issues: A: Share loss in Asia is in line with expectations, and customer-specific issues in biofunctionals are monitored with stabilization expected.